<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02135770</url>
  </required_header>
  <id_info>
    <org_study_id>HLDS01</org_study_id>
    <nct_id>NCT02135770</nct_id>
  </id_info>
  <brief_title>Impact of Low Dose Unfractionated Heparin Treatment on Inflammation in Sepsis</brief_title>
  <official_title>Randomized Control Trial to Assessed the Impact of Low Dose Unfractionated Heparin Treatment on Inflammation in Severe Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indonesia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indonesia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sepsis is a clinical syndrome which infection trigger systemic inflammatory response.
      Uncontrolled inflammatory process leads to multiple organ dysfunction and cause early
      mortality in severe sepsis. Unfractionated heparin is an anticoagulant that widely used
      either for DVT prophylaxis or treatment of disseminated intravascular coagulation. Heparin
      also have an anti-inflammatory effect through downregulates nuclear factor kappa B and tumor
      necrosis factor alpha.

      Aim of this study is to determine effects of low dose unfractionated heparin treatment on
      inflammation in severe sepsis patient.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>inflammation</measure>
    <time_frame>3 days</time_frame>
    <description>determine effects of low dose unfractionated heparin treatment on nuclear factor kappa B, inhibitor kappa B kinase and tumor necrosis factor-alpha.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical outcome</measure>
    <time_frame>14 days</time_frame>
    <description>determine impact of low dose unfractionated heparin on mortality and improvement APACHE II score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">115</enrollment>
  <condition>Severe Sepsis With Septic Shock</condition>
  <condition>Severe Sepsis Without Septic Shock</condition>
  <arm_group>
    <arm_group_label>Unfractionated Heparin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose unfractionated Heparin 10 unit/kgBW/hour continuous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline packed in same form with trial drugs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Unfractionated heparin</intervention_name>
    <description>10 unit/kgBW/hour continuous infusion for 72 hours</description>
    <arm_group_label>Unfractionated Heparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with severe sepsis and septic shock define by revised Sepsis Criteria (2001)

          -  Within 48 hour diagnose sepsis

          -  Agree to participate

        Exclusion Criteria:

          -  Pregnancy and lactation

          -  Severe thrombocytopenia, platelet less than 30.000/mm3

          -  Bleeding or high risk of major bleeding

          -  During anticoagulant treatment

          -  After thrombolytic treatment

          -  Decompensated chronic liver diseases

          -  Chronic kidney diseases on dialysis treatment

          -  During high dose corticosteroid treatment

          -  HIV with CD4 count below 50/mm3

          -  Indication for high dose heparin treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dr. Cipto Mangunkusumo General Hospital</name>
      <address>
        <city>Jakarta</city>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2014</study_first_submitted>
  <study_first_submitted_qc>May 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2014</study_first_posted>
  <last_update_submitted>July 6, 2014</last_update_submitted>
  <last_update_submitted_qc>July 6, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indonesia University</investigator_affiliation>
    <investigator_full_name>Khie Chen Lie</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>heparin</keyword>
  <keyword>sepsis</keyword>
  <keyword>inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

